• Contact
  • Register
  • Sign in
  • FUND SELECTOR ASIA

    SIGN IN

    Access full content on the Fund Selector Asia site, access your saved articles, control email preferences and amend your account details

    Lost your password?
    Forgotten Password
    Cancel

    Not registered?
  • News
    • Latest News
    • Product News
    • People Moves
    • Regulation
  • Views & Interviews
    • Industry Interviews
    • Asset Class in Focus
    • Industry Comment
    • FSA Analysis
  • Data & Research
    • Head To Head
    • Other Data & Research
  • Events
    • Galleries
    • Forum Reviews
    • Awards
  • Special Supplements
    • A Guide To …
    • Fund Insights Directory
    • Bespoke Supplements
  • About us
    • About FSA
    • About Last Word
    • Newsletter Sign-up
    • Editorial Board
X
  • News
    • Latest News
    • Product News
    • People Moves
    • Regulation
  • Views & Interviews
    • Industry Interviews
    • Asset Class in Focus
    • Industry Comment
    • FSA Analysis
  • Data & Research
    • Head To Head
    • Other Data & Research
  • Events
    • Galleries
    • Forum Reviews
    • Awards
  • Special Supplements
    • A Guide To …
    • Fund Insights Directory
    • Bespoke Supplements
  • About us
    • About FSA
    • About Last Word
    • Newsletter Sign-up
    • Editorial Board

MOST VIEWED

1. HEAD-TO-HEAD: Fidelity vs Haitong


2. The problem with growth investing


3. The FSA Spy market buzz – 15 February 2019


4. Huge Stock Connect flows linked to MSCI


5. TT International hunts for China themes


EVENTS

Event Calendar 2019

Tuesday 31st December

View More Events

Asset Class in Focus

Can pharma and biotech ease pain in a financial crisis?

Tags: 2008 GLOBAL FINANCIAL CRISIS | Healthcare

By Piotr Zembrowski, 6 Jun 18

Ten years after the global financial crisis of 2008, FSA notes that pharmaceutical, healthcare and biotech stocks weathered that year better than other sectors.

Not many fund managers and investors would like a repeat of 2008. Around 90% of mutual funds available for sale at that time posted losses for the year. Although 2009 saw the market bottom out and then rally, only 27% of our sample managed to eke out a positive return for the two-year period from the beginning of 2008 to the end of 2009.

The sample includes funds registered for sale in Hong Kong and/or Singapore, with more than 10 years of track record. Funds that have since been liquidated are not included.

The pharmaceuticals, healthcare and bioscience sectors stand out as the ones that suffered least, on average, among all equity sectors, with the average loss of around 20% compared to 46.7% for all equity sectors.

The losses recorded in 2008 by ten funds in the sector varied between -9.8% for the UBS Equity Biotech Fund and and -30.1% of the Pictet Health Fund.

Biotech and pharma stocks were hit no less hard than the broader equity market in the latter half of 2008, as illustrated by a comparison to the MSCI World index (below).

The biotech sector suffered harder than pharmaceuticals, according to a 2009 analysis by Jim Zhang. With a large number of research and development programs put on hold, many companies underwent restructuring. Around 20% of US biotech companies were acquired, filed for bankruptcy or went out of business in 2009, according to a 2011 analysis by Biotech Now.

Nevertheless, the sector as a whole, seen through the prism of mutual funds (keeping in mind the survivor bias, for which we did not correct) appears to have benefited from secular trends, which carried it to great heights in the following eight years. The ten funds in our sample returned on average 176% between 1 January 2010 and 1 January 2018, while the average for all equity funds during the same period was 76%.

Considering the optimistic future many analysts see for pharmaceuticals, healthcare and bioscience in the next decade, it seems worth taking a closer look at these sectors, whether a crisis is imminent or not.

2008-2009 performance of pharma, health and bioscience funds

Returns in US dollars

Ten-year performance of pharma, health and bioscience funds

Returns in US dollars

Leave a comment Cancel reply

You must be logged in to post a comment...

Ads

Related
Content

Sign up to our newsletter
  • Latest News

    FE Advisory Asia Portfolio review – January 2019

    Asset Class in Focus

    Indosuez warns about simmering debt crisis

  • Latest News

    Income fund interest surges in January

    Asset Class in Focus

    Can bond fund bounce continue this year?

  • Head To Head

    HEAD-TO-HEAD: Fidelity vs Haitong

    The FSA Spy market buzz - 06 April 2018

    Latest News

    The FSA Spy market buzz – 15 February 2019

OTHER STORIES FROM LAST WORD...

NFL financial adviser jailed for...

UK middle-income earners ‘sucked into...

‘Uncertain’ Brexit sparks Sicav changes...

More news from IA

How can asset managers really...

Indosuez warns of simmering debt...

Rathbones reboots Luxembourg Sicav range...

More news from EI

Burnett’s European fund launch a...

Mainstream index investors funding ‘invisible’...

Darius McDermott: The fledgling funds...

More news from PA

  • View site map
  • Cookie Policy
  • Privacy Policy
  • Acceptable Use Policy
  • Terms and Conditions
  • Contact

Fund Selector Asia

Published by Last Word Media (HK) Ltd, Suite 2003, 20/F Capitol Centre 1, 5-19 Jardine's Bazaar, Causeway Bay, Hong Kong, SAR. Copyright (c) 2016. All rights reserved. Company Reg. No. 2127095.

Fund Selector Asia provides up-to-the minute news, tools and professional resources for fund selectors, fund analysts, fund influencers, wealth management heads, investment councillors, heads of sales and client-facing wealth advisers throughout English-speaking Asia. No news, articles or content may be reproduced in part or in full without express permission of Fund Selector Asia.

Nothing in this publication amounts to a personal recommendation or endorsement. The material contained in this publication is intended for information only and does not constitute the provision of advice. Neither the writer nor the publisher accepts any responsibility for any loss or damage caused by any use of or reliance on the opinions or views expressed in the publication Fund Selector Asia

We use cookies to give you the best experience. If you do nothing we'll assume that it's okay. Find out more.